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Abstract
Introduction: In primary immunodeﬁciencies there is a failure in the anti-tumor defense. Com-
mon variable immunodeﬁciency (CVID) is one of the most common primary immunodeﬁciencies
characterized by an alteration in the differentiation of B lymphocytes (BL). Epstein-Barr virus
(EBV) is an ubiquitous virus that selectively infects the BL. In patients with immunodeﬁciency,
uncontrolled proliferation of infected BL and the action of viral proteins promote the develop-
ment of lymphomas.
Clinical cases: At the University Hospital Sant Joan de Deu, Barcelona, 28 patients were
diagnosed with CVID from 2000 to 2013. This paper describes four patients who developed
non-Hodgkin’s lymphoma (NHL). The lymphoma was associated with EBV in two of the cases.
Patients were < 18 years old, diagnosed with lymphoma between 4 and 13 years old. Two patients
were treated with rituximab as monotherapy and achieved complete remission. Two patients
were treated with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) and
radiotherapy or rituximab and achieved complete remission.
Conclusions: Early detection of EBV infections and NHL in all patients diagnosed with CVID is
recommended, regardless of age at diagnosis.
© 2016 Hospital Infantil de México Federico Gómez. Published by Masson Doyma México S.A.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Resumen
odeﬁciencias primarias existe un fallo en la defensa antitumoral.
ble común (IDVC) es una de las inmunodeﬁciencias primarias más
por una alteración en la diferenciación de linfocitos B (LB). El virus
virus ubicuo que infecta de manera selectiva los LB. En pacientes
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Introducción: En las inmun
La inmunodeﬁciencia varia
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de Epstein-Barr (EBV) es un
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virales promueve la aparición de linfomas.
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Casos  clínicos:  En  el  Hospital  Universitario  Sant  Joan  de  Déu,  Barcelona,  se  han  diagnosticado
28 pacientes  con  IDVC  del  2000  al  2013.  En  este  trabajo  se  describen  cuatro  que  desarrollaron
linfoma no  Hodgkin  (NHL).  El  linfoma  fue  asociado  a  EBV  en  dos  de  ellos.  Los  pacientes  eran
menores  de  18  an˜os,  con  el  linfoma  diagnosticado  entre  los  4  y  13  an˜os  de  edad.  Dos  de  los
pacientes  fueron  tratados  con  rituximab  como  monoterapia,  y  lograron  la  remisión  completa.
Dos  fueron  tratados  con  CHOP  (ciclofosfamida,  doxorrubicina,  vincristina  y  prednisolona)  y
radioterapia  o  rituximab  y  también  alcanzaron  la  remisión  completa.
Conclusiones:  Se  recomienda  realizar  la  detección  precoz  de  las  infecciones  por  EBV  y  los  NHL
en todos  los  pacientes  con  diagnóstico  de  IDVC,  independientemente  de  la  edad  del  diagnóstico.
©  2016  Hospital  Infantil  de  México  Federico  Gómez.  Publicado  por  Masson  Doyma  México  S.A.
Este  es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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t1. Introduction
Immunodeﬁciencies  are  a  very  broad  group  of  diseases  with
different pathogenetic  mechanisms,  which  have  in  com-
mon a  failure  in  the  regulation  of  the  immune  defense
against foreign  aggressions.  This  failure  in  the  regulation
gives rise  to  diseases  whose  origin  could  be  in  the  alter-
ation of  a  receptor  (for  example,  TOLL  type),  in  the  absence
of an  interleukin  (IL),  in  the  lack  of  function  of  the  B
lymphocytes (BL)  or  T  lymphocytes  (TL)  or  in  the  lack  of
a protein  such  as  MBL  (mannose-binding  lectin).  In  the
end, whatever  the  inductor  genetic  failure,  the  predomi-
nant symptomatology  is  the  presence  of  infections,  although
these patients  also  have  cancers  of  lymphoid  origin  and
autoimmune diseases.1,2 Immunodeﬁciencies  are  classiﬁed
into two  categories:  i)  congenital  or  primary,  almost  always
due to  mutations  or  deletions  of  genes  that  tend  to  be  hered-
itary but  can  also  be  de  novo  mutations;  and  (ii)  acquired
or secondary  due  to  a  disease  that  facilitates  the  loss  of
antibodies or  lymphocytes.  Primary  immunodeﬁciencies  are
associated with  the  genetic  deﬁciencies  mentioned  above.
Examples of  diseases  that  promote  secondary  deﬁciencies
are persistent  infections  such  as  malaria,  chronic  diarrhea
or nephrotic  syndrome.3 Currently  there  have  been  >  70  clin-
ical forms  of  primary  immunodeﬁciencies  identiﬁed.  Due  to
recent advances  in  molecular  biology,  the  molecular  defects
responsible for  an  important  part  of  the  primary  immunode-
ﬁciencies are  known,  with  undeniable  advantages  in  terms  of
the possibility  of  an  accurate  diagnosis,  prenatal  diagnosis  in
affected families,  genetic  counseling  and,  in  some  cases,  the
possibility of  treatment  through  gene  therapy  (Table  1).4,5
1.1.  Immunity  and  cancer
The  relationship  between  immunity  and  cancer  is  well
known. Tumor  cell  antigens  induce  effector  immune
responses that  destroy  tumor  cells.  An  immunological
approach is  increasingly  used  for  the  diagnosis  and  treat-
ment of  cancer.
The immune  defense  against  cancer  is  initially  mediated
by innate  immunity,  composed  of  natural  killer  (NK)  cells
capable of  destroying  tumor  cells.  This  function  potenti-
ates with  interleukins  2  and  12  (IL-2,  IL-12)  and  interferons.
Macrophages eliminate  tumor  cells  using  the  same  mech-
anisms that  eliminate  bacteria.  Activated  macrophages
o
t
l
fynthesize  tumor  necrosis  factor  (TNF)  that  produces  throm-
osis of  the  tumor  blood  vessels.  Antitumor  adaptive
mmunity is  fundamentally  mediated  by  LT  CD8  +  ,  which
re cytotoxic  lymphocytes  sensitized  against  tumor  antigens
apable of  destroying  cancer  cells.  This  speciﬁc  cytotoxic
ffector function  starts  with  antigen-presenting  cells  (den-
ritic cells)  and  is  potentiated  by  stimuli  of  the  LT  CD4  + .
daptive humoral  immunity  consists  of  speciﬁc  IgG  anti-
odies against  tumor  antigens,  but  usually  has  no  effector
unction against  the  tumor  and  only  serves  for  the  diagnosis
nd control  of  tumor  evolution.6
.2.  Epstein-Barr  virus  (EBV)  and  lymphomas
BV  is  a  double-stranded,  ubiquitous  DNA  virus  belonging  to
he herpesvirus  family,  which  selectively  infects  BL,  persist-
ng in  a latent  state.  EBV  antigens  are  expressed  differently,
epending on  the  stage  of  differentiation  of  the  BL  and  have
ifferent activity.  These  viral  antigens  are  expressed  in  the
ucleus, cytoplasm  and  surface  of  infected  cells.  The  ﬁrst
ntigens found  in  a  latent  infection  are  the  Epstein--Barr
uclear antigens  (EBNAs)  of  which  EBNA-LP,  EBNA-2,  EBNA-
A,-3B and  -3C  are  known  and  whose  function  is  the  stimulus
f BL  proliferation.  Latent  membrane  proteins  -1  and  -2
LMP-1 and  LMP-2)  have  oncogenic  properties  because  they
acilitate genomic  instability  and  promote  the  immortal-
zation and  transformation  of  the  infected  BL.  EBV  is  a  BL
olyclonal activator,  independent  of  the  TL  cooperating  sig-
als or  dendritic  cells.  The  in  vitro  BL  infection  promotes  the
ormation of  lymphoblastoid  cell  lines  (LCL)  immortalized
ue to  the  expression  of  the  EBNA,  LMP  proteins  and  various
on-coding miRNAs.  LMP1  and  LMP2A  act  as  constitutively
ctive receptors  that  imitate  the  CD40  signals  of  differen-
iation and  of  the  BL  antigen  receptor,  respectively.  By  this
echanism, EBV  appropriates  the  physiological  pathway  of
ctivation of  the  BL  and  promotes  its  proliferation  and  dif-
erentiation to  memory  cells  in  which  the  virus  may  persist
or the  lifetime  of  the  infected  individual.7
When  a  poor  cytotoxic  TL  CD8  +  response  occurs  due  to
n immunodeﬁciency  of  any  type,  an  uncontrolled  prolifera-
ion of  infected  BL  takes  place  that  increases  the  probability
f errors  occurring  during  DNA  replication,  including  some
hat affect  the  oncogenes  or  tumor  suppressor  genes.  The
oci of  the  immunoglobulins  are  the  most  susceptible  to  suf-
er  translocations.  Translocation  of  the  MYC  gene  to  the
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Table  1  Principal  characteristics  of  primary  immunodeﬁciencies.
Form  of  PID  Examples  of  diseases  Age  at
initiation
Infectious  complications  Other  manifestations
Predominant  antibody
immunodeﬁciency
(humoral)
• X-linked  or  Bruton
agammaglobulinemia
and AR  form
• Transitory  hypogam-
maglobulinemia  of
infancy
• CVID
•  Selective  defect  of
Ig (IgA)
>  6  months
Can  debut  in
adolescence  or
during
adulthood
• Sinopulmonary
infections  by
encapsulated  bacteria
(pneumococcus  H.
inﬂuenzae)
• Gastrointestinal
infections  due  to  Giardia
lamblia,
Cryptosporidium,  and
enterovirus (the  latter
especially in  X-linked
agammaglobulinemia)
• Meningoencephalitis  due
to echo  virus  in  X-linked
agammaglobulinemia
• Autoimmunity:
formation  of
auto-antibodies  and
intestinal
inﬂammatory disease
• Can  be  the  primary
manifestation  of  CVID
• Allergic  disorders
• Lymphoproliferative
syndrome
• Vaccine  viral
disease
Combined
Immunodeﬁciencies
(humoral and  cellular)
• SCID  due  to  defect
in Jak3,  RAG,  ADA
• Reticular  dysgenesis
• Omenn  syndrome
• Hyper-IgM  syndrome
< 6  months  of
life
•  Respiratory,
gastrointestinal  and  skin
infections due  to
opportunistic germs:
-bacteria,
-mycobacteria,
-virus (EBV,  CMV,  VVZ,
enterovirus)
-fungus (Candida,
Aspergillus)
-Pneumocystis  jiroveci
•  Developmental
delay
• Atopic  dermatitis
• Vaccine  viral
disease
Defects of  phagocytes  •  Congenital
neutropenia
(Kostmann  syndrome)
• Cyclic  neutropenia
• Leukocyte  adhesion
defect
• Chronic
granulomatous
disease
Newborn  or
infancy
• Infections  in  skin,  lungs,
and in  the
reticuloendothelial
system  (liver,  spleen)  due
to germs:
-bacteria  (mainly
staphylococcus,
Pseudomonas,
enterobacteria)
-fungus
• Defect  in
cicatrization
• Late  falling  off  of
the umbilical  cord
• Formation  of
granulomas and
abscesses
• Oral  thrush
(neutropenia)
Complement defect  •  Defect  C3
• Defect  C5-C9
Any  age  •  Infections  due  to  Gram
positive bacilli  (defect  C3)
• Infections  due  to
Neisseria (defect  C5-C9)
•  Lupus-like  syndrome
(in  C2-C4  defect
without infectious
manifestations  and  in
C5-C9 defect)
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CPID, primary immunodeﬁciency; ID, immunodeﬁciency; AR, autos
deﬁciency; EBV, Epstein-Barr virus; CMV, cytomegalovirus; VZV, va
ocus  of  the  immunoglobulins  gives  rise  to  an  abnormal
YC expression  associated  with  the  malignant  transforma-
ion and  uncontrolled  proliferation  of  neoplastic  BL  clones,
hich will  constitute  B-cell  lymphoma.  However,  it  is  known
hat in  patients  with  immune  deﬁciencies  without  MYC
ranslocations the  viral  proteins  are  sufﬁcient  to  stimu-
ate the  production  of  BL  clones  that  make  up  the  B
ymphomas.8,9
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d recessive; Ig, immunoglobulin; SCID, severe combined immuno-
a-zoster virus.
In  situations  of  immune  competence,  tumor  cells  are
liminated by  the  defense  mechanisms  described  and  the
irus persists  asymptomatically,  turning  off  its  expression.
ongenital and  secondary  or  acquired  immunodeﬁciencies
re important  risk  factors  for  developing  neoplasms.  In
igure 1 and  Table  2  the  risk  of  leukemias  and  lym-
homas in  diseases  accompanied  by  immunodeﬁciency  are
escribed.
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tFigure  1  Immunodeﬁciency  and  risk  of  non-Hodgkin  lym-
phoma.
1.3.  Common  variable  immunodeﬁciency  and
lymphomas
In  the  Hospital  Universitario  Sant  Joan  de  Déu  (HUSJD)  the
highest frequency  of  neoplasms  in  children  with  primary
immunodeﬁciency has  been  detected  in  patients  with  com-
mon variable  immunodeﬁciency  (CVID)  and  in  all  cases  has
been  associated  with  B  cell  lymphomas.10,11
CVID  is  a  primary  immunodeﬁciency  characterized  by  an
alteration in  the  differentiation  of  B  cells,  with  a  decrease  in
the production  of  immunoglobulins.  It  is  the  most  prevalent
form of  severe  antibody  defects  that  presents  itself  at  a  rate
of 1/25,000  to  1/60,000  individuals.12 CVID  encompasses  a
heterogeneous mixture  of  disorders  due  to  immunoglobulin
and Toll-like  receptors  (TLR9  and  TLR7)  deﬁcits  that  trans-
late in  lack  of  stimulation  of  dendritic  cells  and  interferon
alpha production,  fundamental  mediators  in  the  initiation
of the  antitumoral  innate  immunological  defense.  Clinical
manifestations are  also  heterogeneous  and  include  recur-
rent infections  (in  almost  100%  of  patients),  chronic  lung
disease (30-50%),  autoimmune  diseases  (25%),  gastrointesti-
nal diseases  (20%),  allergic  disease  (33%)  and  elevated
susceptibility to  develop  lymphomas.  Disease  initiation  is
typically described  after  puberty  and  before  the  age  of  30
years, although  there  is  a  bimodal  distribution  with  a  peak
between 1  and  5  years  and  another  between  18  and  25  years.
Table  2  Congenital  diseases  associated  with  an  increased
risk of  leukemia  or  lymphoma.
Disease  Risk*
Down  syndrome  1/74  before  10  years
Fanconi  syndrome  1/12  before  21  years
Bloom  syndrome  1/8  before  26  years
Ataxia-Telangiectasia  12/100
Wiskott-Aldrich syndrome  12/100
IgA deﬁciency  Unknown
Healthy population  1/3000  before  15  years
* Risk is calculated based on the number of people suffering
from leukemia or lymphoma divided by the number of patients
with  congenital diseases. It is compared against the risk of
leukemia or lymphoma in the healthy population (without risk
factors).
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iagnosis  of  the  disease  is  established  by  clinical  and  ana-
ytical criteria  and  after  making  a  differential  diagnosis  with
ther diseases  presenting  with  hypogammaglobulinemia.13
ince  2003,  mutations  in  four  genes  associated  with  CVID
ave been  described,  which  would  represent  10-15%  of
he cases.  The  mutations  described  in  three  of  the  genes
resent an  autosomal  recessive  inheritance  pattern  and  are
xtremely rare:  deﬁcit  in  the  inducible  co-stimulator  of  acti-
ated T-cells  (ICOS),  CD19  deﬁcit  and  deﬁcit  in  the  B-cell
ctivating factor  (BAFF-R).  The  fourth  group  corresponds
o mutations  in  the  TNFRSF12B  gene  (TACI)  described  in
p to  10%  of  patients  with  CVID,  with  an  autosomal  dom-
nant, autosomal  recessive  or  complex  inheritance  pattern
healthy relatives  who  are  carriers  of  the  mutation  have
een found).14
Because  it  is  a  very  heterogeneous  disease  its  progno-
is is  very  variable.  There  are  patients  in  whom  infections
redominate and  are  easier  to  treat  and  respond  well  to
eplacement therapy  with  subcutaneous  or  intravenous  gam-
aglobulin. Another  group  of  patients  have  more  frequent
utoimmune diseases.  In  the  experience  of  the  HUSJD,
he most  common  autoimmune  diseases  in  patients  with
VID are  type  1 diabetes  mellitus,  thyroiditis,  celiac  dis-
ase, systemic  lupus  erythematosus  and  vitiligo;  sometimes
everal of  these  diseases  coexist  in  the  same  patient.  In
hese children,  treatment  with  gammaglobulin  does  not
dequately control  the  autoimmune  disease  that  requires
mmunosuppressant or  substitutive  treatment  of  the  dis-
ase itself.  Children  with  neoplasms  (lymphomas)  have  a
rognosis derived  from  the  optimal  therapeutic  response  to
he anti-CD20  (rituximab)  monoclonal  antibodies.  Cytostatic
reatment is  necessary  in  cases  in  which  there  is  no  response
o rituximab.
Regarding the  prognosis,  it  should  be  kept  in  mind,  as  a
hole, that  treatment  with  gammaglobulin  therapy  reduces
he number  of  infections,  hospitalizations  and  improves
uality of  life.  However,  it  has  not  been  shown  to  pro-
ect from  the  development  of  neoplasms  or  non-infectious
omplications, such  as  autoimmune  diseases  or  granuloma-
ous disease.
.  Clinical cases
n  the  experience  of  the  HUSJD  in  Barcelona,  Spain  the
ighest frequency  of  neoplasms  in  children  with  primary
mmunodeﬁciency has  been  detected  in  patients  with  CVID,
nd in  all  cases  the  neoplasms  have  been  B  cell  lymphomas.11
he  experience  in  regard  to  B  cell  lymphomas  in  chil-
ren diagnosed  with  CVID  in  the  HUSJD  is  described  below.
etween the  years  2000  and  2013  there  were  28  children
etected with  CVID,  diagnosed  according  to  the  criteria  of
he European  Society  for  Immunodeﬁciencies  (ESID)  and  the
an American  Group  of  Immunodeﬁciencies  (PAGID).15 Of  the
8 children  with  CVID,  four  had  B  cell  lymphomas,  two  of
hem associated  with  EBV.
.1.  Case  1e  present  the  case  of  a Caucasian  male  patient.  At  2
onths of  age  he  had  chickenpox  without  complications.
fter 12  months  of  age  he  had  mumps,  bronchitis,  otitis
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edia,  and  recurrent  conjunctivitis.  At  2  years  of  age  he
nderwent tonsillectomy  and  adenoidectomy  for  persistent
titis. Multiple  eye  and  ear  cultures  were  done,  which  were
ositive for  Haemophilus  inﬂuenzae,  Streptococcus  pyo-
enes, Streptococcus  pneumoniae,  Pseudomonas  aeruginosa
nd Staphylococcus  aureus  at  4  years  of  age.  At  this  same
ge he  had  mononucleosis  syndrome  due  to  cytomegalovirus
CMV). At  5  years  of  age  he  was  diagnosed  with  CVID.
reatment with  intravenous  immunoglobulins  was  begun.
e continued  to  have  recurrent  respiratory  tract  infections
espite having  correct  levels  of  IgG.  He  demonstrated  a  lag
n weight/height.
At 8  years  of  age  he  developed  persistent  cervical  and
nguinal adenitis.  Biopsy  of  the  inguinal  lymph  node  showed
vidence of  follicular  hyperplasia  and  PCR  was  positive  for
BV. At  12  years  of  age  he  presented  a  new  episode  of  per-
istent cervical  adenitis.  Biopsy  of  the  cervical  adenopathy
onﬁrmed a  marginal  non-Hodgkin’s  lymphoma  (NHL)  with
CR positive  for  EBV.  NHL  was  immunophenotype  positive  for
D20 and  CD79.  The  extension  study  was  negative.  He  was
lassiﬁed as  stage  III  due  to  the  pathological  characteristics
f the  lymph  nodes  on  computed  tomography  (CT).  Treat-
ent with  rituximab  at  a  dose  of  375  mg/m2 was  decided
pon with  a  ﬁrst  induction  cycle  of  four  weekly  doses,  fol-
owed by  a  phase  of  consolidation  with  four  doses  at  monthly
ntervals and  ﬁnally  the  maintenance  phase  with  two  doses  a
onth until  2  years  of  treatment  were  completed.  Complete
emission was  obtained.
The patient  has  maintained  normal  or  elevated  IgM  lev-
ls, ranging  between  500  and  1700  mg/dl  up  to  10  months
fter the  initiation  of  rituximab.  Hyper-IgM  syndrome  was
uled out  due  to  the  correct  expression  of  CD40  and  CD40L
nd absence  of  genetic  mutations,  and  X-linked  lymphopro-
iferative syndrome  due  to  the  absence  of  mutations  in  the
H2D1A and  XIAP  genes.
.2.  Case  2
e  present  the  case  of  a  female  African-American  patient
ho presented  with  chronic  diarrhea  of  unknown  origin
nd somatic  developmetal  delay  from  early  infancy.  At
he age  of  8  years  she  was  transferred  to  Spain  and
t that  age  was  diagnosed  with  CVID.  Physical  exami-
ation revealed  splenomegaly,  pallor,  cervicolateral  lym-
hadenopathy, bilateral  lung  rales,  hypogammaglobulinemia
nd anemia.  After  immunological  study  that  showed
ecrease in  isohemagglutinins  and  IgG,  IgM  and  IgA,  she
as diagnosed  with  CVID  and  treatment  was  begun  with
ntravenous immunoglobulins.  Minimal  duodenal  lesions  and
ymphocytic inﬂammatory  inﬁltration  were  noted  on  intesti-
al biopsy.  Pulmonary  function  showed  a  mixed  obstructive
nd restrictive  pattern  without  response  to  bronchodila-
ors. Lung  CT  showed  multiple  bilateral  parenchymal  and
ubpleural nodules,  hilar  lymphadenopathy,  and  mediastinal
nd axillary  lymphadenopathy.  Lung  biopsy  conﬁrmed  low-
rade lymphoma  of  marginal  zone,  PCR  positive  for  EBV  and
lassiﬁed as  stage  II.  Extension  study  was  negative.  She  was
reated with  rituximab  as  in  Case  1,  with  complete  remis-
ion.
She persisted  with  chronic  diarrhea  due  to  the  presence
f colon  ulcers  with  PCR  positive  for  CMV  on  biopsies.  At  14
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ears  of  age  she  presented  enterocolitis  with  poor  response
o different  treatments  that  required  total  colectomy
ith ileostomy.  Histological  analysis  showed  indeterminate
nﬂammatory disease.  Currently,  at  the  age  of  16  years,
he remains  stable,  with  secondary  osteoporosis  and  lung
unction with  mixed  pattern.
During  the  diagnosis  of  CVID,  the  percentage  of  B  cells
n peripheral  blood  was  11%,  and  3  years  after  rituximab
s from  0-2%.  Bruton  gammaglobulinemia  was  ruled  out  by
egativity of  mutations  in  the  Bruton  tyrosine  kinase  gene
BTK).
.3.  Case  3
e  present  the  case  of  a  Caucasian  male  with  an  intense
out of  chickenpox  at  18  months  of  age  and  recurrent  bron-
hitis until  3  years  of  age.  At  4  years  of  age  he  was  diagnosed
ith abdominal  Burkitt  lymphoma  with  liver  and  central  ner-
ous system  metastasis  (brain  and  leptomeninges),  classiﬁed
s stage  IV.  Chemotherapy  was  administered  (vincristine,
yclophosphamide and  prednisone,  methotrexate,  ARA-C
nd intrathecal  hydrocortisone)  along  with  cranial  and  spinal
adiotherapy. After  the  initiation  of  chemotherapy  he  devel-
ped herpes  zoster.  At  6  years  of  age  he  was  diagnosed
ith CVID  and  was  started  on  replacement  therapy  of  intra-
enous immunoglobulins.  The  patient  had  low  stature  due
o growth  hormone  deﬁciency,  probably  secondary  to  skull
adiation. He  had  bronchial  asthma  from  7  years  of  age  and
llergic rhinoconjunctivitis  caused  by  seasonal  allergies  to
ild grasses.  Currently,  at  13  years  of  age  he  is  clinically
table, without  infections  or  relapses  of  lymphoma.  He  con-
inues with  low  stature  and  respiratory  allergy.  There  is  no
nformation with  regard  to  the  EBV  status.
.4.  Case  4
e  present  a  female  Caucasian  patient  with  tonsillitis,  otitis
nd pneumonia  between  3  and  4  years  of  age  and  adenoidec-
omy at  5  years  of  age.  At  11  years  of  age  she  presented  with
n inguinal  tumor  diagnosed  as  stage  II  marginal  low  grade
-cell NHL.  Immunohistochemical  study  of  the  lymph  nodes
howed weak  expression  of  CD20,  CD45  and  CD43  and  pos-
tive follicular  expression  for  bcl-2  and  negative  for  CD10
ruling out  follicular  lymphoma).  There  was  monotypical
xpression of  kappa  chains  and  interfollicular  plasmacytoid
ifferentiation, without  expression  of  cyclin  D1  (ruling  out
antle  lymphoma).  With  in  situ  hybridization  there  were  no
ranslocations detected  (14;18)  or  (11;14).  Anti-EBV  IgG  pos-
tive antibodies  were  found  in  plasma.  CHOP  chemotherapy
as begun  (cyclophosphamide,  doxorubicin,  vincristine  and
rednisone) every  21  days  for  6  cycles.  Complete  remission
as obtained.
At 13  years  of  age  she  developed  autoimmune  hemolytic
nemia difﬁcult  to  control  with  steroids  and  which  required
wo cycles  of  rituximab  (375  mg/m2/week,  4  weeks),  with
pace of  6  months  between  relapses.  At  age  15  years,
 year  after  completing  rituximab,  she  developed  B  lym-
hopenia and  persistent  panhypogammaglobulinemia.  The
tudy for  autoimmune  lymphoproliferative  disease  was  pos-
tive and  she  was  diagnosed  with  CVID.  Treatment  was
egun with  intravenous  immunoglobulins.  Subsequently  she
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Table  3  Clinical  and  laboratory  characteristics  associated  with  CVID  patients  who  develop  NHL.
Patient  1  Patient  2  Patient  3  Patient  4
Gender  Male  Female  Male  Female
Consanguinity  No  Yes  No  No
Family  history
- immunodeﬁciency  No  No  No  No
-  autoimmunity  Yes  No  No  Yes
-  malignancy  Yes  No  Yes  Yes
1st  symptom  (age)  Infection  (1  y)  Chronic  diarrhea  (1  y)  Failure  to  thrive  (4  y)  Lymphoma  (11  y)
Age  at  CVID  diagnosis  5  y  11m  8  y  6  y  3  m  15  y  11  m
Phenotypes
No  other  disease-related  complications No  No  Yes No
Cytopenias No  No  No  Yes
Polyclonal  lymphoproliferation  Yes  No  No  No
Unexplained  persistent  enteropathy  No  Yes  No  No
EUROClass  group  smB  +  21loTrnorm smB-  smB  +  21lo B  +
Pediatric classiﬁcation  Group  II  Group  I Group  II  Unknown
IgM  (mg/dL)  at  CVID  diagnosis* 1700  55  347  98
**Gen  TNFRSF  13B
-  exons  1→5 No mutations No  mutations ---- ----
-  variant  A,  NS  Heterozygous  Heterozygous  Heterozygous  Homozygous
-  variant  B,  NS  ----  ----  ----  Heterozygous
*Gen  LRBA
-  variant  A,  NS  ----  Homozygous  ----  ----
-  variant  B,  NS  ----  Homozygous  ----  ----
-  variant  C,  stop  gain  ----  Homozygous  ----  ----
-  variant  F,  NS  ----  ----  Heterozygous  ----
*Gen  ICOSLG
-  variant  NS  Heterozygous  ----  ----  ----
y, year; m, month; NS, nonsynonymous.
*
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** Total IgM in mg/dl at diagnosis.
presented  with  cervical  and  inguinal  adenitis  and  after  a
positron emission  tomography  (PET)  and  inguinal  and  axil-
lary biopsies  were  done,  reactive  lymphoid  hyperplasia  was
reported. At  16  years  of  age  she  developed  right  sub-
mandibular lymphadenopathy,  conﬁrmed  by  biopsy  to  be
MALT type  marginal  lymphoma.  EBV  was  negative  for  in  situ
hybridization and  latent  membrane  protein  was  also  nega-
tive by  immunohistochemistry.  Treatment  was  administered
with rituximab.  At  18  years  of  age  she  was  transferred  to
an adult  treatment  center  due  to  a  recurrence  of  the  MALT
lymphoma. Tables  3  and  4  summarize  the  clinical,  laboratory
characteristics, type  of  lymphoma  and  treatment  given.
3. Discussion
Four  children  diagnosed  with  CVID  who  developed  NHL  are
described. Some  patients  presented  here  have  been  previ-
ously described 11.  Lymphoma  was  associated  with  EBV  in
two of  the  children.  In  addition,  two  patients  developed
lymphoma prior  to  diagnosis  of  CVID.
Complications  of  the  CVID  include  an  increased  risk  of
malignancy, especially  lymphoma  and  gastric  cancer.16--19
Lymphoma  can  be  considered  one  of  the  most  serious
p
1
d
complications  of  CVID.  The  cause  of  the  increased  risk  of
ymphoma in  CVID  seems  to  be  multifactorial  where  the
nteraction of  chronic  infections,  regulation  of  the  immune
ystem and  genetic  disorders  facilitate  the  development  of
he malignant  transformation.20
Kinlen  et  al.21 reported  a  30-fold  increase  in  the  risk
f developing  lymphoma  in  CVID,  whereas  Cunningham-
undles et  al.17 reported  an  increase  of  260-fold.  Results
f the  data  registry  of  Sweden  and  Denmark  showed  an
ncrease of  12  times  in  the  risk  of  lymphoma.22 The  Ital-
an study  of  Quinti  et  al.  supports  an  increase  of  18  times
igher in  the  risk  of  lymphoma,  with  four  cases  of  NHL  during
 years.12 The  Australian  study  with  416  patients  reported  a
tandardized incidence  rate  (SIR)  of  12.1  for  each  1.132  of
HL patients  (95%  CI:  6.03-21.0).18
Lymphomas  that  occur  in  patients  with  CVID  are  most
ommonly of  B-cell  origin.  There  is  a  predominance  of  NHL,
enerally from  the  fourth  to  the  seventh  decade  of  life
nd rarely  in  children.  It  is  commonly  extranodal  and  EBV
egative.23 A  retrospective  study  of  lymph  node  biopsies  of
atients with  primary  immunodeﬁciencies  showed  that  16  of
9 samples  were  positive  for  lymphoma  and  were  patients
iagnosed with  CVID.24 The  majority  were  NHL  with  only  one
ase of  Hodgkin’s  disease  and  EBV  was  not  found  in  any  of  the
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Table  4  Lymphoma  characteristics,  treatment  and  outcome.
Patient  1  Patient  2  Patient  3  Patient  4
Gender  Male  Female  Male  Female
Age* 12  y 8  y  4  y  7m  11  y  11  m
Type NHL  NHL  NHL  NHL
Lymphoma  subtype MALT MALT Burkitt  MALT
Staging  Stage  III  Stage  II  Stage  IV  Stage  II
EBV  tumor  status:  ----  ----  ----  ----
-In  situ  hybridization  +  −  unknown  −
-PCR  +  +  unknown  −
EBV  status  plasma:  PCR-  PCR  +  (whole  blood)  IgM  EBV-  IgG  EBV  +
Primary site  Cervical  lymphadenopathy  Pulmonary  Diffuse  Abdominal  Inguinal  lymphadenopathy
Therapy  Rituximab  Rituximab  CHOP,  Rx  CHOP
Outcome  Remission  Remission  Remission  Recurrence
Therapy  recurrence  ----  ----  ----  Rituximab
* Age at lymphoma diagnosis.
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Ry,  years; m, month; NHL, non-Hodgkin lymphoma; MALT, mucosa-a
phamide, doxorubicin, vincristine, prednisone; Rx, radiation ther
n  situ  samples  by  hybridization.  Patients  of  this  study  were
hildren <  18  years  with  the  lymphoma  diagnosed  between
 and  13  years  of  age  (4  years  of  age  for  the  Burkitt’s  lym-
homa and  from  10  to  13  years  for  MALT  lymphoma).  The
n situ  hybridization  for  EBER1  of  the  EBV  was  positive  in
atient 1  and  negative  in  patients  2  and  4.  There  is  no  infor-
ation available  on  patient  3.  EBV  was  found  by  PCR  in  the
iopsies of  patients  1  and  2.
The  role  of  different  members  of  the  herpesvirus  fam-
ly has  been  investigated  in  patients  with  CVID.  Wheat
t al.  reported  an  important  ﬁnding:  the  presence  of  the
uman herpesvirus  8  (HHV-8)  in  six  of  the  nine  patients  diag-
osed with  CVID  with  interstitial  granulomatous  lung  disease
nd lymphoma  (GLILD).25 One  patient  developed  NHL  and
nother developed  MALT  lymphoma.  In  the  ﬁrst  patient  the
HV-8 virus  was  found  by  qRT-PCR  in  a  high  number  of  copies
n the  malignant  lymph  nodes.  Patient  2  of  our  cases  had  PCR
tudy for  pulmonary  biopsy  negative  for  HHV-8.  Raeiszadeh
t al.  found  an  increase  of  CD8  +  T  cells  speciﬁc  for  CMV
eptides in  patients  with  CVID  compared  with  controls.26
heir  observation  was  related  with  a  higher  prevalence  of
olitis and  subsequent  development  of  NHL.  In  our  series,
atient 1  was  diagnosed  with  infectious  mononucleosis  by
MV before  the  CVID  and  the  lymphoma.  Patient  2  had  PCR
ositive for  CMV  in  colon  biopsies  years  before  lymphoma
reatment.
Treatment of  immunocompetent  patients  with  non-
astric MALT  lymphoma  usually  includes  immunotherapy
ith monoclonal  antibodies  directed  to  CD20  (rituximab)
ith or  without  chemotherapy.  In  patients  with  primary
mmunodeﬁciencies, standard  chemotherapy  regimens  are
ot well  tolerated.  Anti-CD20  monoclonal  antibodies  could
chieve complete  remission  in  patients  with  B-cell  lym-
homas and  CVID.  Rituximab  should  be  considered  as
onotherapy or  associated  with  a  reduced  chemotherapyegime.27--29 Two  of  our  patients  were  treated  with  ritux-
mab as  monotherapy  achieving  a  complete  remission  and
elapse-free after  3  and  6  years  of  follow-up,  respectively.
he third  patient  with  MALT  lymphoma  was  initially  treatediated lymphoma tissue; EBV, Epstein-Barr virus; CHOP, cyclophos-
ith  CHOP.  Treatment  of  the  recurrence  after  4  years  of
emission was  done  with  rituximab,  achieving  a  second  com-
lete  remission.
In conclusion,  CVID  is  a  common  congenital  immu-
odeﬁciency with  clinical  manifestations  of  infections,
utoimmune diseases  and  neoplasms.  In  pediatric  patients
t may  initially  present  as  a neoplastic  disease,  especially
HL, and  is  frequently  associated  with  EBV  infection.  Early
etection of  the  EBV  infections  and  the  NHL  in  all  patients
ith diagnosis  of  CVID  is  recommended,  regardless  of  the
ge at  diagnosis.
thical disclosure
rotection  of  human  and  animal  subjects.  The  authors
eclare that  no  experiments  were  performed  on  humans  or
nimals for  this  study.
onﬁdentiality  of  data.  The  authors  declare  that  no  patient
ata appear  in  this  article.
ight to  privacy  and  informed  consent.  The  authors
eclare that  no  patient  data  appear  in  this  article.
onﬂict of interest
he  authors  declare  no  conﬂict  of  interest.
eferences
1. Martín-Mateos MA. Inmunodeﬁciencias primarias. In: Aso-
ciación Espan˜ola de Pediatría. Moro M, Málaga S, Madero L,
coordinadores. Cruz, Tratado de Pediatría. Madrid: Editorial
Médica  Panamericana; 2014.2. Naidoo R, Ungerer L, Cooper M, Pienaaer S, Eley BS. Primary
immunodeﬁciencies: a 27-year review at a tertiary paedi-
atric hospital in Cape Town, South Africa. J Clin Immunol.
2011;31:99--105.
 1
1
1
2
2
2
2
2
2
2
2
2Primary  immunodeﬁciency  syndromes  and  B-cell  lymphomas
3. Martín-Mateos MA. Inmunodeﬁciencias secundarias. In: Cruz M,
editor. Tratado de Pediatría. Madrid: Ergon; 2011.
4. Al-Herz W,  Boushifa A, Casanova JL, Chapel H, Conley ME,
Cunningham-Rundless CH, et al. Primary immunodeﬁciency dis-
eases: an update on the classiﬁcation from the International
Union  of Immunological Societies Expert Committee for Primary
Immunodeﬁciency. Front Immunol. 2011;2:54.
5.  de Vries E, European Society for Immunodeﬁciencies (ESID)
members. Patient-centered screening for primary immuno-
deﬁciency, a multi-stage diagnostic protocol designed for
non-immunologists: 2011 update. Clin Exp Immunol. 2012;167:
108--19.
6. Abbas AK, Lichtman AH, Pillai S. Inmunología antitumoral. In:
Inmunología Celular y Molecular. Barcelona: Elsevier Saunders;
2013.
7.  McLaughlin-Drubin ME, Munger K. Viruses associated with human
cancer. Biochim Biophys Acta. 2008;1782:127--50.
8.  Cohen JI, Kieff E. An Epstein-Barr virus nuclear protein 2 domain
essential for transformation is a direct transcriptional activator.
J Virol. 1991;65:5880--5.
9. Tomkinson B, Kieff E. Second-site homologous recombination in
Epstein-Barr virus: insertion of type 1 EBNA 3 genes in place
of type 2 has no effect on in vitro infection. J Virol. 1992;66:
780--9.
10.  Barón-Ruiz I, Martín-Mateos MA, Plaza-Martín AM, Giner-
Mun˜oz  MT, Piquer M. Lymphoma as presentation of common
variable immunodeﬁciency. Allergol Immunopathol (Madr).
2009;37:51--3.
11. Piquer Gibert M, Alsina L, Giner Mun˜oz MT, Cruz Martínez O,
Ruiz Echevarria K, Dominguez O, et al. Non-Hodgkin lymphoma
in pediatric patients with common variable immunodeﬁciency.
Eur  J Pediatr. 2015;174:1069--76.
12. Quinti I, Soresina A, Spadaro G, Martino S, Donnanno S, Agostini
C, et al. Long-term follow-up and outcome of a large cohort
of patients with common variable immunodeﬁciency. J Clin
Immunol. 2007;27:308--16.
13. Martín Mateos MA. Diagnóstico precoz de las inmunodeﬁcien-
cias.  Signos guía y pruebas complementarias orientativas para
el pediatra. An Pediatr Contin. 2011;9:145--52.
14.  Orange JS, Glessner JT, Resnick E, Sullivan KE, Lucas M, Ferry
B, et al. Genome-wide association identiﬁes diverse causes of
common variable immunodeﬁciency. J Allergy Clin Immunol.
2011;127:1360--7.
15. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for pri-
mary immunodeﬁciencies. Representing PAGID (Pan-American
Group for Immunodeﬁciency) and ESID (European Society for
Immunodeﬁciencies). Clin Immunol. 1999;93:190--7.
16.  Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher
B, et al. Common variable immunodeﬁciency disorders: division
into distinct clinical phenotypes. Blood. 2008;112:277--86.
225
7.  Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S,
Lieberman P. Incidence of cancer in 98 patients with common
varied immunodeﬁciency. J Clin Immunol. 1987;7:294--9.
8.  Vajdic CM, Mao L, van Leeuwen MT, Kirkpatrick P, Grulich AE,
Riminton S. Are antibody deﬁciency disorders associated with
a narrower range of cancers than other forms of immunodeﬁ-
ciency?  Blood. 2010;116:1228--34.
9. Dhalla F, da Silva SP, Lucas M, Travis S, Chapel H. Review
of  gastric cancer risk factors in patients with common vari-
able immunodeﬁciency disorders, resulting in a proposal for a
surveillance programme. Clin Exp Immunol. 2011;165:1--7.
0. Chua I, Quinti I, Grimbacher B. Lymphoma in common variable
immunodeﬁciency: interplay between immune dysregulation,
infection and genetics. Curr Opin Hematol. 2008;15:368--74.
1.  Kinlen LJ, Webster AD, Bird AG, Haile R, Peto J, Soothill JF,
et al. Prospective study of cancer in patients with hypogamma-
globulinaemia.  Lancet. 1985;1(8423):263--6.
2. Mellemkjaer L, Hammarstrom L, Andersen V, Yuen J,
Heilmann C,  Barington T, et al. Cancer risk among patients
with  IgA deﬁciency or common variable immunodeﬁciency and
their relatives: a combined Danish and Swedish study. Clin Exp
Immunol. 2002;130:495--500.
3. Emir S, Vezir E, Azkur D, Demir HA, Metin A. Characteristics
of  children with non-Hodgkin lymphoma associated with pri-
mary immune deﬁciency diseases: descriptions of ﬁve patients.
Pediatr Hematol Oncol. 2013;30:544--53.
4. Gompels MM, Hodges E, Lock RJ, Angus B, White H, Larkin
A, et al. Lymphoproliferative disease in antibody deﬁ-
ciency: a multi-centre study. Clin Exp Immunol. 2003;134:
314--20.
5. Wheat WH, Cool CD, Morimoto Y, Rai PR, Kirkpatrick CH,
Lindenbaum  BA, et al. Possible role of human herpesvirus 8 in
the  lymphoproliferative disorders in common variable immuno-
deﬁciency. J Exp Med. 2005;202:479--84.
6. Raeiszadeh M, Kopycinski J, Paston SJ, Diss T, Lowdell M, Hardy
GA, et al. The T cell response to persistent herpes virus infec-
tions in common variable immunodeﬁciency. Clin Exp Immunol.
2006;146:234--42.
7. da Silva SP, Resnick E, Lucas M, Lortan J, Patel S,
Cunningham-Rundles C, et al. Lymphoid proliferations of inde-
terminate malignant potential arising in adults with common
variable immunodeﬁciency disorders: unusual case studies and
immunohistological review in the light of possible causative
events.  J Clin Immunol. 2011;31:784--91.
8. Shabbat S, Aharoni J, Sarid L, Ben-Harush M, Kapelushnik J.
Rituximab as monotherapy and in addition to reduced CHOP
in children with primary immunodeﬁciency and non-Hodgkin
lymphoma. Pediatr Blood Cancer. 2009;52:664--6.
9.  Marcus R, Hagenbeek A. The therapeutic use of rituximab in
non-Hodgkin’s lymphoma. Eur J Haematol Suppl. 2007:5--14.
